Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 3

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 3
---
R, and (B) in respect of each RSU, (i) an amount in cash from the Company equal to the Cash Amount, and (ii) one CVR, and in each case, such Option or RSU shall immediately be cancelled. In the event the
exercise price of any Option is greater than or equal to the Cash Amount, neither the Company nor the Purchaser shall be obligated to pay the holder of such Option the Consideration or any other amount in respect of such Option, and the Option shall
be immediately cancelled without any payment.

The Arrangement will result in Shareholders receiving a cash payment upon completion of the
Arrangement, and the Purchaser will retain US$4,000,000 of the Company’s cash balance at Closing as a transaction fee as the Company continues to discontinue and wind-up its business (the
“Discontinuance”).

Following completion of the Arrangement, the Company will become a private company until ultimate
dissolution and all of the Common Shares will be beneficially owned by the Purchaser. In connection with the Arrangement, the Common Shares will be delisted from the Nasdaq Global Select Market (“Nasdaq”) and deregistered under
the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”), in each case, in accordance with applicable Laws, rules and regulations. Following completion of the Arrangement and such deregistration, the Company will
no longer file reports with the U.S. Securities and Exchange Commission (the “SEC”). The Company is also expected to make an application to cease to be a reporting issuer in the Province of Québec under applicable Canadian
securities laws.

An independent transaction committee (the“Transaction Committee”) of the Board has advised the Board that, after careful consideration, including, among other things, thorough consideration of (i)the extent of the strategic review process and the subsequent negotiations with the Purchaser and the Parent and the Transaction Committee’s oversight thereof, (ii)the cash amount expected to be received by the Shareholders and the certainty of value associated therewith, (iii)the potential additional value that may be provided through the CVR Agreement, (iv)the reasonableness of the transaction fee to the Purchaser under the Arrangement, (v)the Company’s prospects in continuing its business on a standalone basis, (vi)the expected return to Shareholders if the Company were alternatively liquidated, (vii)the level of transaction certainty associated with the Arr